Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated at StockNews.com

Research analysts at StockNews.com started coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a research note issued on Thursday. The firm set a “hold” rating on the medical research company’s stock.

Separately, BTIG Research raised shares of Accelerate Diagnostics to a “strong-buy” rating in a research note on Wednesday, December 11th.

Accelerate Diagnostics Price Performance

NASDAQ AXDX opened at $1.20 on Thursday. Accelerate Diagnostics has a 1-year low of $0.73 and a 1-year high of $4.74. The firm has a market capitalization of $30.05 million, a P/E ratio of -0.42 and a beta of 0.56. The business’s 50-day simple moving average is $1.71 and its 200-day simple moving average is $1.55.

Insider Activity at Accelerate Diagnostics

In other news, Director John Patience acquired 200,000 shares of the business’s stock in a transaction on Tuesday, December 3rd. The shares were purchased at an average price of $1.57 per share, for a total transaction of $314,000.00. Following the completion of the purchase, the director now directly owns 653,224 shares of the company’s stock, valued at $1,025,561.68. This represents a 44.13 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 43.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Accelerate Diagnostics

An institutional investor recently bought a new position in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd bought a new stake in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned 0.08% of Accelerate Diagnostics as of its most recent SEC filing. Hedge funds and other institutional investors own 17.14% of the company’s stock.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.